Last reviewed · How we verify
Control Vaccine
Control Vaccine is an inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2.
Control Vaccine is an inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2. Used for Prevention of COVID-19 caused by SARS-CoV-2.
At a glance
| Generic name | Control Vaccine |
|---|---|
| Also known as | Enterovirus Type 71 Vaccine, Inactivated（Human Diploid Cell）, Meningococcal C conjugate vaccine, Varicella vaccine, Locally available Meningococcal conjugate vaccine |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) SARS-CoV-2 virus particles that trigger both humoral (antibody) and cell-mediated immune responses without causing active infection. This approach allows the immune system to recognize and mount a protective response against the virus upon natural exposure. Sinovac's CoronaVac uses this traditional inactivated virus platform, which has a long safety track record in other vaccines.
Approved indications
- Prevention of COVID-19 caused by SARS-CoV-2
Common side effects
- Injection site pain or swelling
- Fatigue
- Myalgia
- Headache
- Fever
Key clinical trials
- A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers (NA)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
- A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |